Gene · 7399
Papers2,630
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 2,630
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Establishing a prognostic model based on immune-related genes and identification of BIRC5 as a potential biomarker for lung adenocarcinoma patients. | BMC Cancer | 2023 | 37741993 | PubTator, text mining | PubMed |
| Characterization of tumor microenvironment and sensitive chemotherapy drugs based on cuproptosis-related signatures in renal cell carcinoma. | Aging (Albany NY) | 2023 | 37728407 | PubTator, text mining | PubMed |
| Construction of an Immunophenoscore-Related Signature for Evaluating Prognosis and Immunotherapy Sensitivity in Ovarian Cancer. | ACS Omega | 2023 | 37720747 | PubTator, text mining | PubMed |
| Expression of the human usherin c.2299delG mutation leads to early-onset auditory loss and stereocilia disorganization. | Commun Biol | 2023 | 37700068 | PubTator, text mining | PubMed |
| THBS1-Mediated Degradation of Collagen via the PI3K/AKT Pathway Facilitates the Metastasis and Poor Prognosis of OSCC. | Int J Mol Sci | 2023 | 37686118 | PubTator, text mining | PubMed |
| A Risk Model for Prognosis and Treatment Response Prediction in Colon Adenocarcinoma Based on Genes Associated with the Characteristics of the Epithelial-Mesenchymal Transition. | Int J Mol Sci | 2023 | 37686013 | PubTator, text mining | PubMed |
| Revisiting Retinal Degeneration Hallmarks: Insights from Molecular Markers and Therapy Perspectives. | Int J Mol Sci | 2023 | 37685886 | PubTator, text mining | PubMed |
| Machine learning-identified stemness features and constructed stemness-related subtype with prognosis, chemotherapy, and immunotherapy responses for non-small cell lung cancer patients. | Stem Cell Res Ther | 2023 | 37674202 | PubTator, text mining | PubMed |
| USH2A variants causing retinitis pigmentosa or Usher syndrome provoke differential retinal phenotypes in disease-specific organoids. | HGG Adv | 2023 | 37654703 | PubTator, text mining | PubMed |
| Investigating the associations of macular edema in retinitis pigmentosa. | Sci Rep | 2023 | 37648803 | PubTator, text mining | PubMed |
| A Comprehensive Report of Intrinsically Disordered Regions in Inherited Retinal Diseases. | Genes (Basel) | 2023 | 37628652 | PubTator, text mining | PubMed |
| MAGI-ACMG: Algorithm for the Classification of Variants According to ACMG and ACGS Recommendations. | Genes (Basel) | 2023 | 37628650 | PubTator, text mining | PubMed |
| The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma. | Front Immunol | 2023 | 37600770 | PubTator, text mining | PubMed |
| Stargardt disease-associated in-frame ABCA4 exon 17 skipping results in significant ABCA4 function. | J Transl Med | 2023 | 37587475 | PubTator, text mining | PubMed |
| PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer. | PLoS One | 2023 | 37582104 | PubTator, text mining | PubMed |
| Rod and Cone Function Measured Objectively by Chromatic Pupil Campimetry Show a Different Preservation Between Distinct Genotypes in Retinitis Pigmentosa. | Invest Ophthalmol Vis Sci | 2023 | 37578425 | PubTator, text mining | PubMed |
| Identification of lysosomal genes associated with prognosis in lung adenocarcinoma. | Transl Lung Cancer Res | 2023 | 37577321 | PubTator, text mining | PubMed |
| The hypoxia-associated genes in immune infiltration and treatment options of lung adenocarcinoma. | PeerJ | 2023 | 37576511 | PubTator, text mining | PubMed |
| Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers. | NPJ Precis Oncol | 2023 | 37558751 | PubTator, text mining | PubMed |
| Familial co-segregation and the emerging role of long-read sequencing to re-classify variants of uncertain significance in inherited retinal diseases. | NPJ Genom Med | 2023 | 37558662 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7399/papers?page=15